Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Edesa Biotech Inc EDSA

Healthcare Biotechnology
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a... see more

Recent & Breaking News (NDAQ:EDSA)

Edesa Biotech to Present at H.C. Wainwright & Co. 6th Annual Israel Conference

Accesswire November 6, 2020

Edesa Biotech Achieves Enrollment Milestone in Dermatitis Study

Accesswire November 3, 2020

Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S.

Accesswire October 19, 2020

Pardeep Nijhawan Acquires Beneficial Ownership of Additional Securities of Edesa Biotech, Inc.

Accesswire September 18, 2020

LD Micro -- 360 Companies Set to Present this Week

Accesswire August 31, 2020

Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results

Accesswire August 12, 2020

Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study

Accesswire July 30, 2020

Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study

Accesswire June 15, 2020

Edesa Biotech Reports Fiscal 2nd Quarter 2020 Results

Accesswire May 15, 2020

Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

Accesswire April 20, 2020

Edesa Biotech to Develop Novel Treatment for Vitiligo in Collaboration with the National Research Council of Canada

Accesswire March 12, 2020

Edesa Biotech Reports Fiscal 1st Quarter 2020 Results

Accesswire February 13, 2020

Edesa Biotech Announces $4.36 million Registered Direct Offering

Accesswire January 6, 2020

Edesa Biotech Reports Financial Results for Short Period Fiscal Year

Accesswire December 12, 2019

Edesa Biotech Reports Positive Healthy Volunteer Data and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions

Accesswire December 3, 2019

Edesa Biotech Announces Upcoming Conference Schedule

Accesswire November 5, 2019

Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study

Accesswire October 21, 2019

Edesa Biotech Receives Approval to Initiate Clinical Study in Patients with Hemorrhoids

Accesswire September 5, 2019

Edesa Biotech to Present at H. C. Wainwright Global Investment Conference

Accesswire August 29, 2019

Edesa Biotech Reports Quarterly Financial Results

Accesswire August 14, 2019